secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001730463-25-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus reports FY2024 net loss $220.7M; AUCATZYL launch on track with 33 U.S. centers
--------------------------------------------------------------------------------

- Net loss $220.7M ($0.86 per share) vs $208.4M ($1.20) in 2023; revenue $10.1M (up from $1.7M).
- Cash and marketable securities $588M at Dec 31, 2024, up from $239.6M, boosted by BioNTech deal and equity financing.
- AUCATZYL commercial launch: 33 authorized treatment centers (covering ~60% of target U.S. patients); targeting 60 by end-2025.
- Obe-cel under EMA/MHRA review with decisions expected H2 2025; Phase 1 SLE trial fully enrolled (6 patients), data at April R&D event.
- BioNTech option for AUTO1/22 expired Feb 8, 2025, not exercised; Blackstone $30M milestone payment triggered by FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/0001730463-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/autl-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001730463-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer